Dallas, Texas (PRWEB) June 17, 2015
The new report Global Depression Drugs Market 2015-2019 says growing public awareness about depression is expected to increase the acceptability of various drugs. The Anxiety and Depression Association of America, Mental Health America, Depression and Bipolar Support Alliance, Suicide Awareness, Voices of Education, and Freedom from Fear are non-profit organizations involved in spreading awareness of depression and its implications. According to the report, WHO has described depression as one of the most disabling illnesses worldwide. In 2012, it was estimated that more than 18 million people suffered from depression in the US, affecting about 25% of women and 10% of men. According to the CDC, about one in every 10 individuals in the US suffers from depression. The prevalence rate of depression is very high because of factors such as genetic vulnerability, lack of proper diagnosis and treatment, and a high degree of association with other medical disorders such as diabetes, stroke, cardiovascular diseases, and psychiatric disorders.
The Global Depression Drugs Market 2015-2019 report is about 107 pages and provides 42 Exhibits to support the market research. The complete report is available at http://www.reportsnreports.com/reports/402200-global-depression-drugs-market-2015-2019.html.
The analysts forecast the global depression drugs market to grow at a CAGR of 5.25% over the period 2014-2019.
The report Global Depression Drugs Market 2015-2019 says, “Despite the increasing number of people suffering from depression, the market for depression drugs is shrinking thanks to alternative treatments. Many patients are opting for complementary and alternative medicines, in combination with conventional treatments. These therapies can include relaxation techniques, massage, meditation, counseling, and art therapy. Homeopathic and Naturopathic medicines have also been found to be helpful in treating depression. These effective alternatives are expected to erode the market share of drugs currently being used for the treatment of depression over the projected period.”
The report Global Depression Drugs Market 2015-2019 states that the expiry of patents of major branded drugs is expected to lead to the erosion of their market share and a fall in revenue.
Market Segmentation, Drivers, Trends and Challenges:
The global depression drugs market is segmented based on the mechanism of action of the drugs used to treat depression, as mentioned below: Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, Monoamine oxidase inhibitors and Others.
The following companies are the key players in the global depression drugs market: Actavis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline and Pfizer.
Purchase a Copy of Global Depression Drugs Market 2015-2019 at http://www.reportsnreports.com/purchase.aspx?name=402200.
Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals.
Market Driver: Rise in patient population
Market Challenge: Threat of expiry of patents
Market Trend: Growing public awareness
Other Related Report:
Global Neurodegenerative Diseases Market 2015-2019 (http://www.reportsnreports.com/reports/390871-global-neurodegenerative-diseases-market-2015-2019.html): The analysts forecast global neurodegenerative diseases market to grow at a CAGR of 4.775 over the period 2014-2019.
The report recognizes the following companies as the key players in Global Neurodegenerative Diseases Market 2015-2019: Biogen, Merck Serono, Novartis, Pfizer, Teva Pharmaceutical and UCB SA.
Other Prominent Vendors in the market are: AB Science, Abbvie, Acorda Therapeutics, Actavis, Active Biotech, Adamas, Akorn,
Archer, Astellas, Auspex, Bayer, Boehringer Ingelheim, Covis, Desitin Arzneimittel, Eli Lilly, Eisai, Endo International, F. Hoffmann-La Roche, FORUM, GlaxoSmithKline Glenmark, Lundbeck, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mitsubishi Tanabe, MorphoSys, Newron Pharmaceuticals, Omeros, Opexa, Orion, Otsuka, BioMedica, Palobiofarma, Prana Biotechnology, Raptor, Sanofi, Siena, SOM, STADA, Takeda Pharmaceutical, TauRx Pharmaceuticals, US WorldMeds, Valeant and Zinfandel.
Infectious Diseases Market in US 2015-2019 (http://www.reportsnreports.com/reports/401713-infectious-diseases-market-in-us-2015-2019.html): The analysts forecast the infectious diseases market in the US to grow at a CAGR of 3.37% over the period 2014-2019.
The following companies are the key players in the infectious diseases market in the US: F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck and Pfizer.
Other Prominent Vendors in the market are: AbbVie, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Sanofi and Vertex.
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email, the details on sales at reportsandreports.com.